Clinical Trial Update: Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial conducted by Fudan University (FUSCC-Thymic 3) is evaluating postoperative adjuvant chemotherapy for thymic carcinoma and is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma

Snippet

Sponsor: Fudan University | Conditions: Thymic Carcinoma | Phase 3 | Status: RECRUITING